Drug Database
Back to search

Poland· PL-100416849

Erleada

A apalutamide product containing apalutamidum, registered in Poland by Janssen-Cilag International N.V.. The same ATC class is registered in 15 of our 19 countries.

ATC L02BB05

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedErleadaATCL02BB05REGISTER NO.PL-100416849PACKS LISTED1CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about apalutamidumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Apalutamide is registered in 15 of 19 countries.

Countries holding a registration under ATC L02BB05 (apalutamide), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 9 of them publish a price we can compare per daily dose
Search apalutamide products by name

Apalutamide · ATC L02BB05

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of apalutamide costs, country by country.

Normalised to the WHO defined daily dose (0.24 g), the median price runs from $0.094 in France to $370.27 in Switzerland — a ×3935 gap.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Apalutamide · price per daily dose (0.24 g)

USD · FX 28 Sept 2026

  • CH Switzerland$370.27
  • FR France$0.094
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Apalutamidum
Manufacturer
Janssen-Cilag International N.V.
Country
Poland (PL)
ATC code
L02BB05
ATC class
Apalutamide
Defined daily dose
0.24 g, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

  • gtin
    05413868117059

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

670 interactions on record for apalutamide.

Graded by severity as the source publishes them — 244 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check apalutamide against other medicinesHow interaction checks work

Apalutamide · interactions on record

670 records

  • 244 severe
  • 412 moderate
  • 14 minor

Most severe, free to view

  • PapaverineA03AD01severe
  • CisaprideA03FA02severe
  • DolasetronA04AA04severe
  • RolapitantA04AD14severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Apalutamide in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All apalutamide products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Erleada
  • Liechtenstein · Erleada
  • Norway · Erleada

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/594bd815-274d-4e06-ada7-0b25c821d95a
GET /v1/drugs/594bd815-274d-4e06-ada7-0b25c821d95a?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki powlekane",
  "source": "urpl",
  "strength": "60 mg",
  "packaging": "Rpz ¦ EU/1/18/1342/003 ¦ 131339\n1 butelka 120 tabl.\nRpz ¦ EU/1/18/1342/001 ¦ 131340\n112 tabl.\n05413868117059 ¦ Rpz ¦ EU/1/18/1342/002 ¦ 131341\n120 tabl. w blistrze",
  "substance": "Apalutamidum 60 mg",
  "common_name": "Apalutamidum",
  "pl_product_id": "100416849",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}
API referenceMCP serverPlans

See everything about apalutamide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console